93 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
17 Apr 24
Departure of Directors or Certain Officers
4:23pm
of the Company described in Exhibit A attached hereto.
2. Services. The Company hereby engages Consultant, and Consultant accepts such engagement … that Consultant’s engagement creates a relationship of confidence and trust between the Company and Consultant with respect to Proprietary Information.
(b
424B3
OCUP
Ocuphire Pharma Inc
16 Feb 24
Prospectus supplement
4:31pm
340 APX3330-treated) for inflammatory (hepatic) and oncology indications, and had demonstrated evidence of target engagement, consistent
8-K
EX-10.1
6tbq6q5qadhmy8m5
27 Nov 23
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
8:45am
8-K
EX-99.1
snibh zpw2bt5hj
2 Nov 23
Ocuphire Corporate Presentation November 2023
8:44am
424B5
1fdvj37n90ktfc c519
14 Aug 23
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
htvse40k
1 Aug 23
Restore Vision & Clarity Ocuphire Corporate Presentation August 2023
11:21am
8-K
EX-99.2
nqydy3c e5sik3
15 May 23
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
8:07am
8-K
EX-99.2
vfurl3gi6dnfpwvvc
12 Aug 22
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update
7:51am